9 4 3 6 4
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.3 Breast Cancer (Dove Med Press)
- 3.4 Clin Epidemiol
- 2.5 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.5 Clin Interv Aging
- 4.7 Drug Des Dev Ther
- 2.7 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.5 Int J Women's Health
- 2.5 Neuropsych Dis Treat
- 2.7 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.3 Ther Clin Risk Manag
- 2.5 J Pain Res
- 2.8 Diabet Metab Synd Ob
- 2.8 Psychol Res Behav Ma
- 3.0 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.7 Risk Manag Healthc Policy
- 4.2 J Inflamm Res
- 2.1 Int J Gen Med
- 4.2 J Hepatocell Carcinoma
- 3.7 J Asthma Allergy
- 1.9 Clin Cosmet Investig Dermatol
- 2.7 J Multidiscip Healthc
已发表论文
实体瘤中整合素 β1 表达增加的预后价值：一项荟萃分析
Authors Sun Q, Zhou C, Ma R, Guo Q, Huang H, Hao J, Liu H, Shi R, Liu B
Received 26 October 2017
Accepted for publication 2 February 2018
Published 29 March 2018 Volume 2018:11 Pages 1787—1799
DOI https://doi.org/10.2147/OTT.S155279
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Colin Mak
Peer reviewer comments 2
Editor who approved publication: Dr Carlos Vigil Gonzales
Abstract: Integrin-beta 1
(ITGB1) is aberrantly overexpressed or downregulated in solid cancers; however,
its prognostic value remains controversial. Therefore, we conducted a
meta-analysis to explore whether ITGB1 expression is correlated with overall
survival (OS) and the clinicopathological characteristics of patients with
solid cancers. We systematically searched the PubMed, Embase, and Web of
Science databases for eligible studies published up to June 1, 2017. In total,
22 studies involving 3,666 patients were included. A sensitivity analysis was
performed to assess the validity and reliability of the pooled OS. Among the 22
studies, 7 focused on lung cancer, 3 focused on colorectal cancer, 6 focused on
breast cancer, 3 involved melanoma, and 3 involved pancreatic cancer. The
pooled results showed that high ITGB1 expression was significantly associated
with worse OS in lung cancer (pooled hazard ratio [HR]=1.78, 95% CI:
1.19–2.65, p <0.05) and breast cancer
(pooled HR=1.88, 95% CI: 1.46–2.42, p <0.01). In
addition, a significant association was observed between high ITGB1 expression
and disease-free survival in breast cancer (pooled HR=1.63, 95% CI:
1.17–2.25, p <0.001) and pancreatic cancer
(pooled HR=2.49, 95% CI: 1.35–4.61, p <0.001).
However, high ITGB1 expression was not related to OS in colorectal cancer,
pancreatic cancer, or melanoma. The pooled HRs used to evaluate the prognostic
value of increased ITGB1 expression in lung cancer, breast cancer, and
pancreatic cancer were not significantly altered, which indicates that the
pooled results were robust. The results of this study indicate that the
prognostic value of decreased ITGB1 expression varies among solid cancers.
Keywords: ITGB1, solid cancer, prognosis, meta-analysis
Keywords: ITGB1, solid cancer, prognosis, meta-analysis
